Two recent events have brought stents into the spotlight for the future of treatment of the superficial femoral artery (SFA), says Frank J. Criado, MD, FACS, FSVM, clinical editor of Vascular Disease Management, in the VDM blog. One is presentation of results of a retrospective review of 517 patients in which more than half treated for claudication or critical limb ischemia with stenting of the SFA had primary patency at 5 years.
The other is the recent FDA approval of the Zilver PTX stent (Cook Medical) for peripheral arterial disease in the SFA. In a trial of the PTX stent, key outcomes include that 8 out of 10 patients treated with the device had patent arteries at 12 months compared to only 3 out of 10 patients treated with angioplasty alone.
Read more from Dr. Criado at “Stents Tighten Their Grip on the SFA.”